ACUTE LYMPHOCYTIC LEUKEMIA
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0030, NCI-2011-02941, NCT01424982
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-23, NCI-2016-01196, NCT02711852
Mesenchymal Stem Cells in Treating Patients with Acute Respiratory Distress Syndrome Undergoing Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0327, NCI-2016-01184, NCT02804945
Blinatumomab after Donor Stem Cell Transplant in Treating Patients with Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2015-0576, NCI-2016-01182, NCT02807883
Tacrolimus, Bortezomib, and Anti-thymocyte Globulin in Preventing Low Toxicity GVHD in Patients with Blood Cancer Undergoing Donor Blood Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Prevention, Supportive care, Treatment
Age: 18 to 75
Trial IDs: Winship3258-16, NCI-2016-01035, IRB00082499, NCT02877082
Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: R1979-ONC-1504, NCI-2016-01243, NCT02651662
Ibrutinib, Dasatinib, and Prednisone in Treating Older Patients with Newly Diagnosed Philadelphia Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 60 and over
Trial IDs: HCI85188, NCI-2016-01268, NCT02815059
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Status: Active
Phase: No phase specified
Type: Health services research, Supportive care
Age: Any age
Trial IDs: 10-CBA, NCI-2014-02344, NCI-2013-01898, NCI-2014-01018, NCT01351545
CERVICAL CANCER
Laparoscopic Approach to Cervical Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LACC001, NCI-2014-01556, NCT00614211
Alisertib and Sapanisertib in Treating Patients with Locally Advanced or Metastatic HPV-Associated Cancer
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0689, NCI-2016-01190, NCT02812056
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
Status: Enrolling by invitation
Phase: No phase specified
Type: Diagnostic
Age: 21 and over
Trial IDs: BDS-USLHPV, NCI-2016-01209, NCT02267876
CHRONIC MYELOGENOUS LEUKEMIA
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Axitinib and Bosutinib in Treating Patients with Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0787, NCI-2016-01188, NCT02782403
Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TGR-1202-201-CLL, NCI-2016-01161, NCT02742090
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-23, NCI-2016-01196, NCT02711852
Mesenchymal Stem Cells in Treating Patients with Acute Respiratory Distress Syndrome Undergoing Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0327, NCI-2016-01184, NCT02804945
Tacrolimus, Bortezomib, and Anti-thymocyte Globulin in Preventing Low Toxicity GVHD in Patients with Blood Cancer Undergoing Donor Blood Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Prevention, Supportive care, Treatment
Age: 18 to 75
Trial IDs: Winship3258-16, NCI-2016-01035, IRB00082499, NCT02877082
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Status: Active
Phase: No phase specified
Type: Health services research, Supportive care
Age: Any age
Trial IDs: 10-CBA, NCI-2014-02344, NCI-2013-01898, NCI-2014-01018, NCT01351545
ESOPHAGEAL CANCER
Study of ONO-4538 in Unresectable Advanced or Recurrent Esophageal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 20 and over
Trial IDs: ONO-4538-24/CA209-473, NCI-2016-01219, NCT02569242
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Pembrolizumab and Palliative Radiation Therapy in Treating Patients with Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16099, NCI-2016-00686, NCT02830594
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients with Stage IIB-IIIC Esophageal Cancer
Status: Not yet active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: IRB00012071, NCI-2016-01093, NCT02857218
HODGKIN LYMPHOMA
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status: Enrolling by invitation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-23, NCI-2016-01196, NCT02711852
Mesenchymal Stem Cells in Treating Patients with Acute Respiratory Distress Syndrome Undergoing Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0327, NCI-2016-01184, NCT02804945
Ibrutinib in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2016-033, NCI-2016-00879, NCT02824029
Fludarabine Phosphate, Cyclophosphamide, and Total Body Irradiation or Busulfan before Donor Bone Marrow or Peripheral Blood Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients with Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 120931, NCI-2013-01956, NCT02623439
Ibrutinib in Treating Patients with Refractory or Relapsed Lymphoma after Donor Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC BMT 1651, NCI-2016-01246, NCT02869633
Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: R1979-ONC-1504, NCI-2016-01243, NCT02651662
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Status: Active
Phase: No phase specified
Type: Health services research, Supportive care
Age: Any age
Trial IDs: 10-CBA, NCI-2014-02344, NCI-2013-01898, NCI-2014-01018, NCT01351545
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients with Advanced Cancer
Status: Not yet active
Phase: No phase specified
Type: Health services research
Age: 18 and over
Trial IDs: EAQ152, NCI-2015-02253, NCT02823652
LIVER CANCER
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-240, NCI-2016-01269, 2015-004567-36, NCT02702401
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16329, NCI-2016-01171, 2015-004699-31, I3O-MC-JSBF, NCT02711553
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients with Advanced Liver Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 16I01, NCI-2016-01001, STU00203003, NCT02837029
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Unresectable or Metastatic Cholangiocarcinoma
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1542, NCI-2016-01057, NCT02856568
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: H3B-6527-G000-101, NCI-2016-01306, 2016-001915-19, NCT02834780
MRI in Planning Stereotactic Body Radiation Therapy in Patients with Stage I-III Liver Cancer or Liver Metastases
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: 21 and over
Trial IDs: Pro00071159, NCI-2016-01176, NCT02722395
MELANOMA
An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCAGN 1876-101, NCI-2016-01221, NCT02697591
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol(R)
Status: Active
Phase: Phase II
Type: Treatment
Age: 14 and over
Trial IDs: ONC2014-001, NCI-2016-01295, 1R44CA183075-01A1, NCT02423863
Infliximab With Prednisone or Methylprednisolone With Prednisone Combination Treatment in Immune Related or Severe Diarrhea Patients Treated With Yervoy and/or Opdivo
Status: Not yet active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: CA209-601, NCI-2016-01172, NCT02763761
Azacitidine and Pembrolizumab in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0069, NCI-2016-01185, NCT02816021
Talimogene Laherparepvec with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-224, NCI-2016-01215, NCT02819843
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO28054, NCI-2013-01159, 2012-003143-29, NCT01765556
Decitabine and Tetrahydrouridine with or without Celecoxib in Treating Patients with Lung Metastases Undergoing Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0146, NCI-2016-01160, NCT02839694
Hsp90 Inhibitor XL888, Vemurafenib, and Cobimetinib in Treating Patients with BRAF Mutated Stage IIIB-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18597, NCI-2016-01261, NCT02721459
Biomarker Analysis in Blood Samples from Patients With Stage I-IV Melanoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: UPCC 15613, NCI-2014-00592, NCT02828345
Pembrolizumab and Stereotactic Radiosurgery in Treating Patients with Melanoma or Non-Small Cell Lung Cancer That Has Spread to the Brain
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RAD3179-16, NCI-2016-00718, IRB00086461, NCT02858869
PROSTATE CANCER
Cabazitaxel and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#261, NCI-2016-00961,
NCT02844582
Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients with Localized Prostate Cancer Before Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9628, NCI-2016-01027, NCT02849990
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-199, NCI-2016-01244, 2015-003644-40, NCT02787005
Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 45 to 80
Trial IDs: GCP-10100, NCI-2016-01262, NCT02766543
ARN-509, Abiraterone Acetate, Prednisone, Leuprolide Acetate, and Stereotactic, Ultra-hypofractionated Radiation Therapy in Treating Patients with Very High Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-334, NCI-2016-01304, NCT02772588
Stereotactic Body Radiation Therapy in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-001580, NCI-2016-00188, JCCCID608, NCT02830165
Carbon-11 Acetate PET/CT Imaging in Treating Patients with Prostate Cancer
Status: Not yet active
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 16-000260, NCI-2016-01080, NCT02826395
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients with Advanced Cancer
Status: Not yet active
Phase: No phase specified
Type: Health services research
Age: 18 and over
Trial IDs: EAQ152, NCI-2015-02253, NCT02823652
18F-DCFPyL PET/CT in Imaging Patients with Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: J15216, NCI-2016-00953, CRMS-62968, IRB00084971, NCT02825875
18F-DCFPyL PET/CT in Monitoring Treatment Response in Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: J15232,
NCI-2016-01248, CRMS-63060, IRB00082289,
NCT02856100